Immunogen, Inc. (IMGN) Misses Q3 Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Price: $31.25 --0%
Financial Fact:
Clinical materials reimbursement: 46K
Today's EPS Names:
OMID, SICP, SCKT, More
Financial Fact:
Clinical materials reimbursement: 46K
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
Immunogen, Inc. (NASDAQ: IMGN) reported Q3 EPS of ($0.44), $0.17 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $6.9 million versus the consensus estimate of $13.28 million.
For earnings history and earnings-related data on Immunogen, Inc. (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- These 2 Chip Stocks Are Piper Sandler’s Top Picks Into 2027
- SpaceX shares continue higher following Anthropic's $120.5bn AI deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
